Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: A Chinese hospital system perspective

Clinical Chemistry and Laboratory Medicine

Volumn 55, Issue 4, 2017, Pages 561-570

  Stojanovic, Ivana ^a   Schneider, John E ^b   Wei, Long ^c   Hong, Zhan ^d   Keane, Clara ^b   Schuetz, Philipp ^e  

^a Health Economist   (United States)

^b Avalon Health Economics   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^e CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

antibiotic stewardship; Chinese health system; cost saving; economic evaluation; procalcitonin; respiratory infection

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFDINIR; CEFEPIME; CEFOPERAZONE PLUS SULBACTAM; CEFOTIAM; CEFTRIAXONE; CEFUROXIME; CILASTATIN; CLARITHROMYCIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PROCALCITONIN; SULTAMICILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CALCITONIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BRONCHITIS; CHINA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COST CONTROL; DRUG COST; ECONOMIC EVALUATION; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL MANAGEMENT; HOSPITAL PLANNING; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; UPPER RESPIRATORY TRACT INFECTION; URBAN AREA; VENTILATOR ASSOCIATED PNEUMONIA; ACUTE DISEASE; BLOOD; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; HOSPITAL EMERGENCY SERVICE; HOSPITAL PATIENT; INTENSIVE CARE UNIT; RESPIRATORY TRACT INFECTIONS;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; BIOMARKERS; CALCITONIN; CHINA; COST-BENEFIT ANALYSIS; EMERGENCY SERVICE, HOSPITAL; HUMANS; INPATIENTS; INTENSIVE CARE UNITS; MODELS, ECONOMIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS;

EID: 85016012562     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2016-0349     Document Type: Article

References (84)

1. Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 2010;28:1001-13.
2. Assasi N, Schwartz L, Tarride JE, Goeree R, Xie F. Economic evaluations conducted for assessment of genetic testing technologies: a systematic review. Genet Test Mol Biomarkers 2012;16:1322-35.
3. Beaulieu M, de Denus S, Lachaine J. Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics 2010;11:1573-90.
4. Chowdhury P, Kehl D, Choudhary R, Maisel A. The use of biomarkers in the patient with heart failure. Curr Cardiol Rep 2013;15:372.
5. Diop D. Maximizing the quality and cost-effectiveness of cardiac care with laboratory technology and process improvements. J Cardiovasc Manag 2003;14:19-23.
6. Schuetz P, Amin DN, Greenwald JL. Role of procalcitonin in managing adult patients with respiratory tract infections. Chest 2012;141:1063-73.
7. Shen B, Hwang J. The clinical utility of precision medicine: properly assessing the value of emerging diagnostic tests. Clin Pharmacol Ther 2010;88:754-6.
8. Wong W. A health plan's integration of molecular diagnostics and the impact on treatment pathways for quality care. Manag Care 2008;17(7 Suppl 7):13-6; discussion 7-8.
9. Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013;19:216-28.
10. Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007;30:556-73.
11. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010;14:203.
12. Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci 2013;50: 23-36.
13. File TM, Jr. New diagnostic tests for pneumonia: what is their role in clinical practice? Clin Chest Med 2011;32:417-30.
14. Gerber JS, Prasad PA, Fiks AG, Localio AR, Grundmeier RW, Bell LM, et al. Effect of an outpatient antimicrobial stewardship intervention on broad-spectrum antibiotic prescribing by primary care pediatricians: a randomized trial. J Am Med Assoc 2013;309:2345-52.
15. Gjelstad S, Hoye S, Straand J, Brekke M, Dalen I, Lindbaek M. Improving antibiotic prescribing in acute respiratory tract infections: cluster randomised trial from Norwegian general practice (prescription peer academic detailing (Rx-PAD) study). Br Med J 2013;347:f4403.
16. Lippi G, Meschi T, Cervellin G. Inflammatory biomarkers for the diagnosis, monitoring and follow-up of community-acquired pneumonia: clinical evidence and perspectives. Eur J Intern Med 2011;22:460-5.
17. Luyt CE, Combes A, Trouillet JL, Chastre J. Biomarkers to optimize antibiotic therapy for pneumonia due to multidrug-resistant pathogens. Clin Chest Med 2011;32:431-8.
18. Mira JP, Max A, Burgel PR. The role of biomarkers in communityacquired pneumonia: predicting mortality and response to adjunctive therapy. Crit Care 2008;12(Suppl 6):S5.
19. Mitsuma SF, Mansour MK, Dekker JP, Kim J, Rahman MZ, Tweed-Kent A, et al. Promising new assays and technologies for the diagnosis and management of infectious diseases. Clin Infect Dis 2013;56:996-1002.
20. O'Brien DJ, Gould IM. Maximizing the impact of antimicrobial stewardship: the role of diagnostics, national and international efforts. Curr Opin Infect Dis 2013;26:352-8.
21. Reinhart K, Hartog CS. Biomarkers as a guide for antimicrobial therapy. Int J Antimicrob Agents 2010;36(Suppl 2):S17-21.
22. Schuetz P, Christ-Crain M, Muller B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care 2007;13:578-85.
23. Schuetz P, Haubitz S, Mueller B. Do sepsis biomarkers in the emergency room allow transition from bundled sepsis care to personalized patient care? Curr Opin Crit care 2012;18:341-9.
24. Schuetz P, Litke A, Albrich WC, Mueller B. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis 2013;26:159-67.
25. Seligman R, Ramos-Lima LF, Oliveira Vdo A, Sanvicente C, Pacheco EF, Dalla Rosa K. Biomarkers in community-acquired pneumonia: a state-of-the-art review. Clinics (Sao Paulo) 2012;67:1321-5.
26. Upadhyay S, Niederman MS. Biomarkers: what is their benefit in the identification of infection, severity assessment, and management of community-acquired pneumonia? Infect Dis Clin North Am 2013;27:19-31.
27. Ventetuolo CE, Levy MM. Biomarkers: diagnosis and risk assessment in sepsis. Clin Chest Med 2008;29:591-603, vii.
28. Vincent JL, Beumier M. Diagnostic and prognostic markers in sepsis. Expert Rev Anti Infect Ther 2013;11:265-75.
29. Aabenhus R, Jensen JU. Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting: are we there yet? Prim Care Respir J 2011;20:360-7.
30. Fazili T, Endy T, Javaid W, Maskey M. Role of procalcitonin in guiding antibiotic therapy. Am J Health Syst Pharm 2012;69:2057-61.
31. Foushee JA, Hope NH, Grace EE. Applying biomarkers to clinical practice: a guide for utilizing procalcitonin assays. J Antimicrob Chemother 2012;67:2560-9.
32. Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis 2012;73:221-7.
33. Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012;55:651-62.
34. Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012;9:CD007498.
35. Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, Bassetti S, et al. Influence of procalcitonin on decision to start antibiotic treatment in patients with a lower respiratory tract infection: insight from the observational multicentric ProREAL surveillance. Eur J Clin Microbiol Infect Dis 2013;32:51-60.
36. Geiser MM. Procalcitonin Testing in the Puzzle of Sepsis. BioMerieux Report, 2013.
37. Soni N, Samson D, Galaydick J, Vats V, Huang E, Aronson N, et al. Procalcitonin-guided antibiotic therapy: a systematic review and meta-analysis. J Hosp Med 2013;8:530-40.
38. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and metaanalysis. Lancet Infect Dis 2013;13:426-35.
39. Wu MH, Lin CC, Huang SL, Shih HM, Wang CC, Lee CC, et al. Can procalcitonin tests aid in identifying bacterial infections associated with influenza pneumonia? A systematic review and meta-analysis. Influenza Other Respir Viruses 2013;7:349-55.
40. Yu CW, Juan LI, Wu MH, Shen CJ, Wu JY, Lee CC. Systematic review and meta-analysis of the diagnostic accuracy of procalcitonin, C-reactive protein and white blood cell count for suspected acute appendicitis. Br J Surg 2013;100:322-9.
41. Berg P, Lindhardt BO. The role of procalcitonin in adult patients with community-acquired pneumonia-a systematic review. Dan Med J 2012;59:A4357.
42. Briel M, Christ-Crain M, Young J, Schuetz P, Huber P, Periat P, et al. Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners [ISRCTN73182671]. BMC Fam Pract 2005;6:34.
43. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008;168:2000-7; discussion 7-8.
44. Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010;8:575-87.
45. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011;171:1322-31.
46. Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitoninguided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009;37:497-507.
47. Wolff M, Bouadma L. What procalcitonin brings to management of sepsis in the ICU. Crit Care 2010;14:1007.
48. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis 2011;53:379-87.
49. Albrich WC, Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in "real life": an international, multicenter poststudy survey (ProREAL). Arch Intern Med 2012;172:715-22.
50. Deliberato RO, Marra AR, Sanches PR, Martino MD, Ferreira CE, Pasternak J, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Micr Infect Dis 2013;76:266-71.
51. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011;39:1792-9.
52. Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Evid Based Child Health 2013;8:1297-371.
53. Soni N, Samson D, Galaydick J, Vats V, Pitrak D, Aronson N. Procalcitonin-guided antibiotic therapy. Comparative effectiveness review No. 78. AHRQ Publication No. 12(13)-EHC124-EF. Rockville, MD: Agency for Healthcare Research and Quality: Blue Cross and Blue Shield Association Technology Evaluation Center Evidencebased Practice Center under Contract No. 290-2007-10058-I, 2012.
54. Chen M, Wang L, Chen W, Zhang L, Jiang H, Mao W. Does economic incentive matter for rational use of medicine? China's experience from the essential medicines program. Pharmaco-Economics 2014;32:245-55.
55. Thomson S, Osborn R, Squires D, Reed SJ. International Profiles of Health Care Systems, 2011. The Commonwealth Fund, November 2011.
56. WHO. Chronic Respiratory Diseases. Geneva, Switzerland: World Health Organization, 2005.
57. LIU Yue-hua WJ-h, Zhang Jie. Emergency Disease spectrum in China: based on Hospital Database From Beijing. Beijing, China: Tsinghua University, May 2015.
58. He R, Luo B, Hu C, Li Y, Niu R. Differences in distribution and drug sensitivity of pathogens in lower respiratory tract infections between general wards and RICU. J Thorac Dis 2014;6:1403-10.
59. Wang J, Wang Q, Bi Z. [A surveillance on acute respiratory infection]. Zhonghua liu xing bing xue za zhi 1994;15:141-4.
60. Zhang Y, Yao Z, Zhan S, Yang Z, Wei D, Zhang J, et al. Disease burden of intensive care unit-acquired pneumonia in China: a systematic review and meta-analysis. Intern J Infect Dis 2014;29:84-90.
61. Cheng A, Ren N, Wen X. A nosocomial infection point-prevalence survey: results and analysis of 193 Hospitals in China in 2001. Chin J Nosocomiol 2002;12:561-3.
62. Fu C, Yang J. Influence of carrying out zero price addition policy of drugs on public hospital expenses in shenzhen. Chinese Hospital Management 2013;33:4-6.
63. He S, Chen B, Li W, Yan J, Chen L, Wang X, et al. Ventilator-associated pneumonia after cardiac surgery: a meta-analysis and systematic review. J Thorac Cardiovasc Surg 2014;148:3148-55. e1-5.
64. Zhang X, Wang R, Di X, Liu B, Liu Y. Different microbiological and clinical aspects of lower respiratory tract infections between China and European/American countries. J Thorac Dis 2014;6:134-42.
65. Li Y, Xu J, Wang F, Wang B, Liu L, Hou W, et al. Overprescribing in China, driven by financial incentives, results in very high use of antibiotics, injections, and corticosteroids. Health Aff (Millwood) 2012;31:1075-82.
66. Huang HH, Zhang YY, Xiu QY, Zhou X, Huang SG, Lu Q, et al. Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients. Eur J Clin Microbiol Infect Dis 2006;25:369-74.
67. Liu YN, Cao B, Wang H, Chen LA, She DY, Zhao TM, et al. [Adult hospital acquired pneumonia: a multicenter study on microbiology and clinical characteristics of patients from 9 Chinese cities]. Zhonghua jie he he hu xi za zhi 2012;35:739-46.
68. He LX. [Guidelines for the diagnosis and treatment of community-acquired pneumonia: learning and practicing]. Zhonghua jie he he hu xi za zhi 2006;29:649-50.
69. Li C, Ren N, Wen X, Zhou P, Huang X, Gong R, et al. Changes in antimicrobial use prevalence in China: results from five point prevalence studies. PLoS One 2013;8:e82785.
70. Ding JG, Sun QF, Li KC, Zheng MH, Miao XH, Ni W, et al. Retrospective analysis of nosocomial infections in the intensive care unit of a tertiary hospital in China during 2003 and 2007. BMC Infect Dis 2009;9:115.
71. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
72. Gao J, Prasad N. Chronic obstructive pulmonary disease in China: the potential role of indacaterol. J Thorac Dis 2013;5:549-58.
73. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72.
74. Liu Y, Chen M, Zhao T, Wang H, Wang R, Cai B, et al. Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population. BMC Infect Dis 2009;9:31.
75. Long W, Deng X, Zhang Y, Lu G, Xie J, Tang J. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 2011;16:819-24.
76. Schuetz P, Briel M, Christ-Crain M, Wolbers M, Stolz D, Tamm M, et al. Procalcitonin to initiate or withhold antibiotics in acute respiratory tract infections (Protocol). Cochrane Database Syst Rev 2008. Art. No.: CD007498.
77. Cai BQ, Cai SX, Chen RC, Cui LY, Feng YL, Gu YT, et al. Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People's Republic of China. Int J Chron Obstruct Pulmon Dis 2014;9:381-95.
78. Li ZP, Huang JQ, Tang KJ. [Retrospective studies on 713 cases chronic obstructive pulmonary disease]. Zhonghua liu xing bing xue za zhi 2003;24:722-4.
79. Schuetz P, Balk R, Briel M, Kutz A, Christ-Crain M, Stolz D, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med 2015;53:583-92.
80. van Zanten AR, Engelfriet PM, van Dillen K, van Veen M, Nuijten MJ, Polderman KH. Importance of nondrug costs of intravenous antibiotic therapy. Crit Care 2003;7:R184-90.
81. Michaelidis CI, Zimmerman RK, Nowalk MP, Fine MJ, Smith KJ. Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults. J Gen Intern Med 2014;29:579-86.
82. Lee M, Snyder A. The role of procalcitonin in communityacquired pneumonia: a literature review. Adv Emerg Nurs J 2012;34:259-71.
83. Bishop BM, Bon JJ, Trienski TL, Pasquale TR, Martin BR, File TM, Jr. Effect of introducing procalcitonin on antimicrobial therapy duration in patients with sepsis and/or pneumonia in the intensive care unit. Ann Pharmacother 2014;48:577-83.
84. Cohen B, Larson EL, Stone PW, Neidell M, Glied SA. Factors associated with variation in estimates of the cost of resistant infections. Med Care 2010;48:767-75.